CRKL and metastatic malignant neoplasm in the lymph nodes: In addition to poor tumor differentiation, lymph node metastasis, resection margin, and advanced TNM stage, univariate survival analyses revealed that the expression of GAB2, CRKL, FRS2 and the co-expression of GAB2/CRKL/FRS2 were also indicators for poor clinical outcome.